ASH 2024: inMIND study results position Monjuvi as a promising therapy for R/R follicular lymphoma
At the American Society of Hematology (ASH) Annual Meeting, held on 7-10 December, early results from the double-blind, randomised, placebo-controlled, Phase III inMIND clinical trial were presented. The trial evaluated the efficacy and safety of the …